This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.

This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.

This product is a fully synthetic cholesterol-lowering drug and a hydroxymethylglutaryl coenzyme A (HMG-Coa) reductase inhibitor that can convert HMG-CoA into 3-methyl-3,5-dihydroxyvaleric acid. The site of action of this product is in the liver, which has the effects of inhibiting the synthesis of endogenous cholesterol, reducing the cholesterol content in liver cells, stimulating the synthesis of low-density lipoprotein (LDL) receptors, increasing the uptake of LDL particles, and reducing the total cholesterol concentration in plasma.

This product is a fully synthetic cholesterol-lowering drug and a hydroxymethylglutaryl coenzyme A (HMG-Coa) reductase inhibitor that can convert HMG-CoA into 3-methyl-3,5-dihydroxyvaleric acid. The site of action of this product is in the liver, which has the effects of inhibiting the synthesis of endogenous cholesterol, reducing the cholesterol content in liver cells, stimulating the synthesis of low-density lipoprotein (LDL) receptors, increasing the uptake of LDL particles, and reducing the total cholesterol concentration in plasma.

This product is an angiotensin converting enzyme inhibitor. After oral administration, it is hydrolyzed into Enalaprilat in the body, which strongly inhibits angiotensin converting enzyme, reduces the content of angiotensin II, causes systemic vasodilation, and causes blood pressure reduction. It has a significant antihypertensive effect on rat models of renal hypertension II, renal hypertension I, and spontaneous hypertension.